Binge Eating Curtailed by Higher Doses of ADHD Medication

This article originally appeared here.
Share this content:
Binge Eating Curtailed by Higher Doses of ADHD Medication
Binge Eating Curtailed by Higher Doses of ADHD Medication

(HealthDay News) -- At higher doses, the attention-deficit/hyperactivity disorder (ADHD) drug lisdexamfetamine dimesylate (Vyvanse) curtails the excessive food consumption that characterizes binge-eating disorder, preliminary research suggests. The findings were reported online Jan. 14 in JAMA Psychiatry.

James Mitchell, M.D., president of the Neuropsychiatric Research Institute in Fargo, N.D., and colleagues tracked outcomes among 260 patients with moderate to severe binge-eating disorder between 2011 and 2012. All of the participants were between 18 and 55 years old, and none had a diagnosis of any additional psychiatric disorders, such as ADHD, anorexia, or bulimia. The volunteers were divided into four groups for 11 weeks. The first group received 30 mg of lisdexamfetamine daily, while the second and third groups started with 30 mg a day, increasing to 50 or 70 mg (respectively) within three weeks. A fourth group took an inactive placebo pill.

Lisdexamfetamine did not appear to help curtail binge eating at the lowest dosage. But people taking the higher doses experienced a bigger drop in the number of days they binged each week compared with the placebo group, the researchers found. Also, while only about one-fifth (21.3 percent) of those treated with a placebo were able to stay binge-free for a month, that figure increased to 42.2 and 50.0 percent among the 50- and 70-mg drug groups, respectively.

The study authors point out that their investigation remains ongoing, and their findings must be reconfirmed.

The 14-week study was funded by Shire Development, the manufacturer of lisdexamfetamine.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »